Fanapt

Quick links to important sections

Fanapt

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fanapt

What is Fanapt? Overview

Property Description
Active Ingredient Iloperidone
Form Oral Tablet
Pharmacological Class Atypical Antipsychotic (SGA)
General Purpose Stabilizing thought processes and perception
Origin Synthetic (Benzisoxazole derivative)

What is Fanapt? Classification and Composition

Fanapt is the trade name for the prescription-only medication containing the active ingredient Iloperidone. This substance, a synthetic compound, is part of the Atypical Antipsychotic class, also widely recognized as a Second-Generation Antipsychotic (SGA). The medication is presented as a single-ingredient product in an oral tablet form. Iloperidone is structurally characterized as a piperidinyl-benzisoxazole derivative, a feature that helps define its specific pharmacological properties. The oral tablet formulation is key to its intended use, providing a standardized, consistent dose of the active substance for systemic absorption.

Understanding Iloperidone’s Mechanism and General Purpose

Iloperidone works primarily by achieving a careful balance in the activity of crucial brain messengers, particularly dopamine and serotonin, which are involved in regulating mood and cognition. The mechanism involves the drug acting as an antagonist, binding to and blocking several receptors, including dopamine D2 and serotonin 5-HT2A receptors. This mechanism is clinically recognized to assist in managing severe mental health conditions in adults associated with altered brain chemistry. Its general purpose is therefore to stabilize thought processes, perception, and emotional responses in affected patients.

Fanapt vs. Other Antipsychotics: The Atypical Distinction

The Atypical Antipsychotic classification of Iloperidone stems from its multi-receptor action, which includes notable affinity for both dopamine and serotonin pathways. An important differentiating factor for Iloperidone is its profile which often presents a lower likelihood of causing certain motor-related side effects, such as extrapyramidal symptoms (EPS), compared to some other medicines in the class. This distinction provides a crucial alternative for adult patients requiring neurochemical stabilization.

What side effects are possible with Fanapt?

Possible Side Effects and Safety Information

The safety profile of Fanapt (iloperidone) is formally classified based on the incidence and nature of adverse reactions observed in clinical trials, as documented by regulatory bodies.


Officially Classified Common Adverse Reactions

The most commonly observed adverse reactions (incidence ge 5% and at least twice the rate of placebo) are primarily related to effects on the nervous and cardiovascular systems. These include:

System-Organ Class (SOC) Adverse Reaction (AR)
Nervous System Disorders Dizziness, Somnolence (sleepiness), Fatigue
Cardiovascular Disorders Tachycardia (fast heartbeat), Orthostatic Hypotension (blood pressure drop upon standing)
Other Dry mouth, Nasal congestion, Weight increased

Orthostatic hypotension and associated symptoms like dizziness are noted by the regulator to be most common at the initiation of therapy or during dose increases.


Documented Serious Safety Concerns

The official labeling includes prominent warnings for serious, though less frequent, conditions. These include:

  • Increased Mortality in Elderly Patients with Dementia-Related Psychosis: A Boxed Warning states that Fanapt is not approved for this patient population due to an increased risk of death, which appears to be cardiovascular or infectious in nature.
  • QT Prolongation: The drug can prolong the QT interval, an electrical change in the heart, which may be associated with arrhythmia and the risk of sudden death.
  • Neuroleptic Malignant Syndrome (NMS) and Tardive Dyskinesia (TD): Both are rare but potentially serious syndromes associated with antipsychotic use, involving severe muscle rigidity and uncontrolled movements, respectively.

Other Safety Constraints

The safety profile also documents metabolic changes (hyperglycemia, dyslipidemia, and weight gain) and specific population constraints. Use is not recommended for patients with severe hepatic impairment. Caution is advised in patients with a history of seizures or conditions that lower the seizure threshold, and in those at risk for electrolyte imbalances (hypokalemia/hypomagnesemia).

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Fanapt (iloperidone) may cause an exaggeration of the drug’s known effects, presenting as a serious clinical situation that requires immediate medical attention.

Documented Overdose Symptoms

The most commonly reported clinical manifestations of overdose include:

  • Central Nervous System Effects: Severe drowsiness, profound sedation, or stupor.
  • Cardiovascular Effects: Tachycardia (fast heart rate) and hypotension (low blood pressure).
  • Motor/Musculoskeletal Effects: Extrapyramidal symptoms (abnormal or uncontrolled movements).

Critical Overdose Risks and Management

A critical risk in overdose is the potential for QTc interval prolongation, which necessitates continuous and intensive cardiovascular monitoring (ECG) until the patient has fully recovered. Overdoses have been reported from single ingestions up to 576 mg, with associated symptoms requiring clinical intervention.

There is no known specific antidote for Fanapt overdose. Treatment is strictly supportive, focusing on managing the symptoms and maintaining vital functions.

When to Seek Emergency Medical Help

Immediate emergency medical help (call 911 or equivalent) must be sought if an overdose is suspected. This is especially urgent if the affected person has:

  • Collapsed or lost consciousness.
  • Trouble breathing or shallow breathing.
  • Had a seizure.
  • Cannot be awakened.

Therapeutic Uses of Fanapt

What Fanapt Treats: Main Uses and Benefits

Fanapt (iloperidone) is used in adult patients to provide symptomatic relief and stabilization across primary domains of severe mental illness. This medication is applied across therapeutic areas where additional symptomatic support is needed. It is commonly used to help with schizophrenia and for the acute management of manic or mixed episodes associated with Bipolar I Disorder.


Symptom Relief and Therapeutic Focus

The therapeutic focus is on addressing symptoms that interfere with daily functioning and create noticeable physiological strain. The medication plays a role in managing disruptive psychotic symptoms such as hallucinations and delusions, and may assist in supporting daily functional well-being during acute episodes of mood instability (mania). It is also considered relevant for easing the burden of negative symptoms like apathy and social withdrawal.

“This medication is applied in situations involving certain distressing symptoms and supports the patient during difficult episodes by easing distress.”

Quick Fact: Relief for Psychosis

Quick Fact: Relief for Psychosis Fanapt is applied in clinical settings that involve acute or unstable symptom patterns, helping to ease the overall symptom burden by contributing to thought process and perception management. This contributes to improved comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus overview on Iloperidone

Eligibility and Restrictions for Use

Who Can and Cannot Use Fanapt?

Fanapt (iloperidone) eligibility is strictly defined by regulatory authorities based on age, existing medical conditions, and known sensitivities. The medicine is approved for use only in adults aged 18 years and older for its specified indications.


Absolute Restrictions and Contraindications

Population Group Eligibility Status Basis for Restriction
Pediatric Patients (Children/Adolescents) Safety and effectiveness not established. Age restriction
Elderly with Dementia-Related Psychosis Contraindicated (Not approved). Increased risk of death
Known Hypersensitivity Contraindicated. Risk of allergic reactions
Congenital Long QT Syndrome Avoid Use. Cardiac risk
Severe Hepatic Impairment Not recommended. Organ function limitation

Conditional Use Populations

Use requires special consideration in certain populations. The medicine should be used during pregnancy only if clearly needed, as exposure in the third trimester carries a risk of extrapyramidal or withdrawal symptoms in the neonate. Nursing mothers are advised not to breastfeed while taking Fanapt. Patients who are known CYP2D6 poor metabolizers require a mandated dose reduction to maintain eligibility.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Fanapt (iloperidone) is defined by its metabolism via specific liver enzymes and its potential for pharmacodynamic effects. Officially documented interactions fall into categories requiring either mandatory dosage restrictions or advised against co-administration.

Pharmacokinetic Interactions: Exposure Modification

Co-administration with strong inhibitors of the cytochrome P450 enzymes CYP2D6 (e.g., fluoxetine, paroxetine) or CYP3A4 (e.g., ketoconazole, clarithromycin) results in a pharmacokinetic interaction. This officially increases iloperidone systemic exposure (AUC/Cmax) and requires a 50% reduction in the iloperidone dosage. The dose must be adjusted back to the original level upon withdrawal of the strong enzyme inhibitor. This exposure modification also applies to individuals identified as CYP2D6 Poor Metabolizers due to naturally reduced clearance.

Pharmacodynamic Interactions and Restrictions

The regulatory label advises against co-administration with other medicinal products known to prolong the QTc interval due to the additive risk of serious arrhythmia. Additionally, co-administration with other CNS depressants (including alcohol) or hypotensive agents may result in additive pharmacodynamic effects, such as increased sedation or orthostatic hypotension. Iloperidone may be administered with or without food, as no clinically significant drug-food interaction is documented.

Mechanism of Action

Dual Modulation of Dopamine and Serotonin Receptors

Iloperidone's primary mechanism involves the antagonism (blockade) of two critical neurochemical sites: the dopamine D2 receptor and the serotonin 5 -HT2 A receptor. This dual mechanism of action modulates dysregulated signaling in central pathways involving perception and cognition. Furthermore, the 5 -HT2 A blockade modifies dopamine signaling in the motor control system, influencing pathway activity associated with motor control.


Alpha-1 Adrenergic Receptor Blockade and Vascular Tone

The drug has a high affinity for the alpha-1 (alpha1) adrenergic receptor, a key target in the autonomic nervous system. Blocking this receptor causes vasodilation (widening of blood vessels), resulting in reduced peripheral vascular tone. This predictable physiological adjustment dictates the necessary slow, gradual increase in dosing to allow the body to adapt to the circulatory effects.


Ancillary Receptor Fine-Tuning

Iloperidone also engages other targets, including the D3 and alpha2 C receptors, with specific binding profiles. This ancillary modulation engages multiple receptor targets, contributing to a comprehensive profile of regional neurotransmitter modulation across various neural pathways. This activity contributes to the final multi-system physiological profile of the compound.

Dosage and Administration Information

How Fanapt is Used: Official Administration Guidelines

Fanapt (iloperidone) is an atypical antipsychotic administered orally as a tablet. The administration follows a highly specific protocol, primarily involving a gradual dose titration to manage certain physiological responses at the start of treatment.


Dosing and Administration Schedule

Category Official Instruction
Route of Administration Oral Tablet only.
Frequency Administered twice daily (BID) in divided doses.
Starting Dose 1 mg twice daily.
Recommended Maintenance 12 mg to 24 mg total per day.
Timing Relative to Meals May be taken with or without food.

The Mandatory Titration Protocol

Usage begins with a 7-day dose titration schedule, where the daily dose is incrementally increased to reach the recommended maintenance dose. For example, the daily dosage may start at 2 mg (1 mg twice daily) and gradually increase until it reaches the target, which typically occurs by the seventh day of administration. If a patient misses more than three consecutive days of taking the medication, the official label requires the full 7-day titration schedule to be re-initiated.


Population-Specific Dosing

Administration also includes specific rules for certain adult populations. For individuals identified as poor metabolizers of the enzyme CYP2D6, the total daily dose must be reduced by one-half. Conversely, the use of iloperidone is not recommended for patients who have severe hepatic impairment (severe liver problems). The medication's safety and effectiveness have not been established for use in children and adolescents.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fanapt


Evidence for Use in Acute Schizophrenia

Fanapt (iloperidone) was evaluated in research exploring how symptoms change over time related to schizophrenia. The initial research involved short-term, randomized, double-blind, placebo-controlled trials (RCTs) which examined how symptoms change over time. These studies research examined changes in the severity of symptoms over periods typically lasting four to six weeks. Standardized tools, like the Positive and Negative Syndrome Scale (PANSS), were applied in studies examining symptom intensity to track how symptoms evolved in the observed populations across the study periods.

Evidence for Use in Acute Bipolar I Mania

Research has been studied for the acute treatment of adults with manic or mixed episodes associated with Bipolar I Disorder. This research involved Phase 3 randomized, placebo-controlled trials that focused on conditions associated with acute or disruptive episodes. The primary focus of these acute trials was on outcomes describing episodic or acute changes. Researchers studies monitored changes using standardized tools such as the Young Mania Rating Scale (YMRS) to track the intensity of manic symptoms.

Long-Term Research and Follow-up Studies

Beyond the initial short-term trials for acute symptoms, other research was evaluated in research examining long-term outcomes for maintenance treatment. These studies explored whether the patterns observed in the short-term were observed over longer periods. The follow-up durations were limited in these controlled settings, typically extending up to about 26 weeks. As such, there is limited information for long-term outcomes under controlled trial conditions, and long-term effects are not fully established beyond the study periods.

What is Still Uncertain About Fanapt

While research has been studied for Fanapt's acute use, several areas remain insufficiently understood. Comparative evidence is lacking when looking at direct, head-to-head trials against certain other treatments for these conditions. Furthermore, the existing research evidence is limited regarding the long-term impact on functional recovery, employment, and overall quality of life. There is limited information for long-term outcomes for how Fanapt's outcomes related to systemic or functional imbalance translate over years of use in diverse patient groups.

Key Studies & References

  1. Iloperidone: in schizophrenia

Frequently Asked Questions (FAQ)

Common questions about Fanapt (FAQ)


Q: What is the typical time frame to notice the full benefits of Fanapt?

Clinical trials examining changes in symptoms were generally conducted over short periods of four to six weeks. Due to the regulatory requirement for a slow, gradual increase in dosage (titration), the official product information notes that the full clinical effect may be slightly delayed compared to some other treatments.


Q: What type of monitoring is usually required for a patient starting Fanapt (e.g., blood tests, EKG)?

Monitoring is typically recommended for potential changes in heart rhythm, often requiring an EKG (electrocardiogram) and checks for electrolyte imbalances. Additionally, regular monitoring for metabolic changes, including blood glucose, lipid levels (cholesterol and triglycerides), and weight, is generally suggested by regulatory information.


Q: Is the tiredness or sleepiness caused by Fanapt a temporary or long-term side effect?

Somnolence (sleepiness) and fatigue are common side effects reported in clinical trials. The product labeling includes a warning regarding the potential for cognitive and motor impairment, suggesting patients should be aware of this effect, especially when starting treatment.


Q: What are the potential risks if a patient suddenly stops taking Fanapt?

If the medication is stopped for more than three consecutive days, regulatory guidance states that the full initial titration schedule is required to be re-initiated. Additionally, official information indicates that newborns whose mothers used the drug during the third trimester of pregnancy may be at risk for abnormal muscle movements or withdrawal symptoms.


Q: Has Fanapt been studied for its effectiveness in preventing relapse of symptoms?

Studies have explored the drug's role in maintenance treatment. One controlled clinical study examined whether continued treatment was associated with a delay in time to relapse in adults with schizophrenia who had achieved stability.


Q: Is there any difference in efficacy or side effects between taking Fanapt with or without food?

Official product information states that the medication may be taken with or without food. Pharmacokinetic studies show that taking the dose with food does not significantly affect the total amount of the drug that the body absorbs.


Q: Can Fanapt be used for conditions like anxiety, bipolar depression, or major depressive disorder?

The medication is currently indicated only for the treatment of schizophrenia in adults and for the short-term treatment of manic or mixed episodes related to Bipolar I Disorder in adults. Regulatory approval is restricted to these specific mental health conditions.


Q: Does Fanapt carry a high risk for changes in blood sugar or cholesterol levels?

The drug is associated with metabolic changes, which is a formal warning in the product labeling. These changes include increases in blood sugar (hyperglycemia), increases in cholesterol and triglyceride levels (dyslipidemia), and weight gain.


Q: Does Fanapt affect a person's ability to drive or operate heavy machinery?

The product labeling includes a specific warning about the potential for cognitive and motor impairment, such as reduced alertness. Official guidance includes a warning that patients should not drive or operate hazardous machinery until they are reasonably sure that the medication does not negatively affect their abilities.


Q: Can Fanapt increase the risk of seizures in certain patients?

The regulatory label advises caution when the medication is used in individuals with a history of seizures or those with medical conditions that could lower the body's seizure threshold.


Q: What is the half-life of Fanapt, and what does this mean for how the drug stays in the body?

The elimination half-life of the active ingredient, iloperidone, is approximately 18 to 33 hours, depending on an individual's metabolism. This figure describes the time it typically takes for the body to reduce the amount of the drug in the system by half.


Q: How does Fanapt affect the body's ability to regulate temperature, especially in the heat?

Official safety warnings state that the drug may disrupt the body’s ability to regulate its core temperature. Regulatory guidance advises patients to take precautions, such as avoiding strenuous activity or excessive heat, to prevent overheating.


Q: What is the risk of taking Fanapt while pregnant or breastfeeding?

Antipsychotic use during the third trimester of pregnancy has a risk of causing abnormal muscle movements or withdrawal symptoms in newborns. For nursing mothers, the decision must be made whether to stop taking the drug or to discontinue breastfeeding.


Q: Does Fanapt have side effects that affect sexual function or libido?

Official safety information reports that the drug is associated with hormonal changes, specifically high prolactin levels (hyperprolactinemia), which can lead to sexual dysfunction. Additionally, rare cases of priapism (a prolonged, painful erection) have been reported.


Q: Does Fanapt cause hormonal changes, such as increased prolactin levels?

Yes, the product labeling includes a specific warning about the risk of hyperprolactinemia, which refers to increased levels of the hormone prolactin. This hormonal change is associated with this class of medication.


Q: How does Fanapt affect mood, such as the potential for mood swings or changes in thinking?

The product labeling includes a warning for the potential for changes in thinking (cognitive impairment). Official adverse event reporting also notes behavioral changes.


Q: What are the signs of an allergic reaction to Fanapt that require immediate medical attention?

Severe hypersensitivity reactions, including anaphylaxis and angioedema, have been reported. Signs include rapid swelling of the face, lips, mouth, or tongue, and difficulty breathing, which should be immediately reported to a healthcare provider.


Q: Does Fanapt interact with over-the-counter medications or herbal remedies?

Interactions can occur with medications that affect specific liver enzymes (CYP2D6 and CYP3A4) responsible for breaking down the drug. This includes some over-the-counter medications, supplements, and herbal remedies, as well as any drug that prolongs the heart's QT interval or lowers blood pressure.


Q: Can Fanapt cause restless leg movements (akathisia)?

The drug is associated with extrapyramidal symptoms (EPS), which is a term for various movement disorders. Akathisia, characterized by a feeling of inner restlessness, is a type of EPS that has been reported as an adverse reaction in clinical trials.


Q: Is Fanapt available as a generic medication?

Yes, the active ingredient in Fanapt is iloperidone. Generic iloperidone tablets have been approved by the Food and Drug Administration (FDA) and are available.


Q: Are there reports of Fanapt affecting memory or concentration?

The regulatory label includes a warning regarding the potential for cognitive and motor impairment. This warning directly relates to a person's ability to concentrate, think clearly, and perform complex tasks.


Q: What is the importance of getting regular check-ups while taking Fanapt?

The official product labeling mandates specific monitoring for several serious risks, including changes to heart rhythm, blood pressure, blood glucose, and blood cell counts. Regulatory information outlines the need for regular monitoring to track these potential safety concerns.

How should Fanapt be stored and disposed of?

Storage Requirements

Fanapt (iloperidone) tablets must be stored at Controlled Room Temperature, defined officially as 25 C (77 F), with permitted fluctuations between 15 C and 30 C (59 F and 86 F). The product's stability depends on protection from environmental factors; therefore, it must be stored away from light and moisture.

Container and Child Safety

The tablets should be kept in the original container and the container must be sealed tightly closed. As a safety requirement, the medication must be stored out of the reach of children.

Disposal Instructions

Unused or expired Fanapt must be disposed of properly according to official guidelines. Health authorities recommend utilizing a drug take-back program when available. Disposal instructions state the product should not be flushed down a toilet or discarded in household waste unless specifically authorized.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fanapt found in:

A-Z Index: